1             Key Insights

2             Peripheral Neuropathy Market Overview at a Glance

2.1         Market Share (%) Distribution of Peripheral Neuropathy in 2017

2.2         Market Share (%) Distribution of Peripheral Neuropathy in 2026

3             Executive Summary of Peripheral Neuropathy

4             Peripheral Neuropathy: Disease Background and Overview

4.1         Introduction

4.2         Causes

4.3         Pathophysiology

4.4         Symptoms

4.5         Risk Factors

4.6         Diagnosis

5             Diagnostic Algorithm for Peripheral Neuropathy

6             Clinical Algorithm for Epileptic Spasms (Infantile Spasms) By Texas Children’s Hospital

7             Epidemiology and Patient Population

7.1         Key Findings

7.2         9MM Total Prevalent Population of Peripheral Neuropathy

7.3         9MM Total Diagnosed Prevalent Population of Peripheral Neuropathy

7.4         9MM Age-specific Prevalence of Peripheral Neuropathy

7.5         9MM Gender-specific Prevalence of Peripheral Neuropathy

7.6         9MM Type-specific Prevalence of Peripheral Neuropathy

8             Country Wise-Epidemiology of Peripheral Neuropathy

8.1         Assumptions and Rationale: 9MM Countries

8.2         United States

8.2.1      Assumptions and Rationale

8.2.2      Total Prevalent Population of Peripheral Neuropathy in the United States

8.2.3      Total Diagnosed Prevalent Population of Peripheral Neuropathy in the United States

8.2.4      Age-specific Diagnosed Prevalent Population of Peripheral Neuropathy in the United States

8.2.5      Gender- specific Diagnosed Prevalent Population of Peripheral Neuropathy in the United States

8.2.6      Type- specific Diagnosed Prevalent Population of Peripheral Neuropathy in the United States

8.3         EU5 Countries

8.3.1      Assumptions and Rationale

8.4         Germany

8.4.1      Total Prevalent Population of Peripheral Neuropathy in Germany

8.4.2      Total Diagnosed Prevalent Population of Peripheral Neuropathy in Germany

8.4.3      Age-specific Diagnosed Prevalent Population of Peripheral Neuropathy in Germany

8.4.4      Gender- specific Diagnosed Prevalent Population of Peripheral Neuropathy in Germany

8.4.5      Type- specific Diagnosed Prevalent Population of Peripheral Neuropathy in Germany

8.5         France

8.5.1      Total Prevalent Population of Peripheral Neuropathy in France

8.5.2      Total Diagnosed Prevalent Population of Peripheral Neuropathy in France

8.5.3      Age-specific Diagnosed Prevalent Population of Peripheral Neuropathy in France

8.5.4      Gender- specific Diagnosed Prevalent Population of Peripheral Neuropathy in France

8.5.5      Type- specific Diagnosed Prevalent Population of Peripheral Neuropathy in France

8.6         Italy

8.6.1      Total Prevalent Population of Peripheral Neuropathy in Italy

8.6.2      Total Diagnosed Prevalent Population of Peripheral Neuropathy in Italy

8.6.3      Age-specific Diagnosed Prevalent Population of Peripheral Neuropathy in Italy

8.6.4      Gender- specific Diagnosed Prevalent Population of Peripheral Neuropathy in Italy

8.6.5      Type- specific Diagnosed Prevalent Population of Peripheral Neuropathy in Italy

8.7         Spain

8.7.1      Total Prevalent Population of Peripheral Neuropathy in Spain

8.7.2      Total Diagnosed Prevalent Population of Peripheral Neuropathy in Spain

8.7.3      Age-specific Diagnosed Prevalent Population of Peripheral Neuropathy in Spain

8.7.4      Gender- specific Diagnosed Prevalent Population of Peripheral Neuropathy in Spain

8.7.5      Type- specific Diagnosed Prevalent Population of Peripheral Neuropathy in Spain

8.8         United Kingdom

8.8.1      Total Prevalent Population of Peripheral Neuropathy in the United Kingdom

8.8.2      Total Diagnosed Prevalent Population of Peripheral Neuropathy in the United Kingdom

8.8.3      Age-specific Diagnosed Prevalent Population of Peripheral Neuropathy in the United Kingdom

8.8.4      Gender- specific Diagnosed Prevalent Population of Peripheral Neuropathy in the United Kingdom

8.8.5      Type- specific Diagnosed Prevalent Population of Peripheral Neuropathy in the United Kingdom

8.9         Australia

8.9.1      Assumptions and Rationale

8.9.2      Total Prevalent Population of Peripheral Neuropathy in Australia

8.9.3      Total Diagnosed Prevalent Population of Peripheral Neuropathy in Australia

8.9.4      Age-specific Diagnosed Prevalent Population of Peripheral Neuropathy in Australia

8.9.5      Gender- specific Diagnosed Prevalent Population of Peripheral Neuropathy in Australia

8.9.6      Type- specific Diagnosed Prevalent Population of Peripheral Neuropathy in Australia

8.1         China

8.10.1    Assumptions and Rationale

8.10.2    Total Prevalent Population of Peripheral Neuropathy in China

8.10.3    Total Diagnosed Prevalent Population of Peripheral Neuropathy in China

8.10.4    Age-specific Diagnosed Prevalent Population of Peripheral Neuropathy in China

8.10.5    Gender- specific Diagnosed Prevalent Population of Peripheral Neuropathy in China

8.10.6    Type- specific Diagnosed Prevalent Population of Peripheral Neuropathy in China

8.11       Japan

8.11.1    Assumptions and Rationale

8.11.2    Total Prevalent Population of Peripheral Neuropathy in Japan

8.11.3    Total Diagnosed Prevalent Population of Peripheral Neuropathy in Japan

8.11.4    Age-specific Diagnosed Prevalent Population of Peripheral Neuropathy in Japan

8.11.5    Gender- specific Diagnosed Prevalent Population of Peripheral Neuropathy in Japan

8.11.6    Type- specific Diagnosed Prevalent Population of Peripheral Neuropathy in Japan

9             Treatment

10           Treatment Algorithm for Peripheral Neuropathy

11           Emerging Drugs

11.1       Calmangafodipir: PledPharma; Solasia Pharma

11.1.1    Product Description

11.1.2    Other Development Activities

11.1.3    Clinical Development

11.1.4    Clinical Trials Information

11.1.5    Safety and Efficacy

11.1.6    Product Profile

11.2       Engensis: Helixmith

11.2.1    Product Description

11.2.2    Other Development Activities

11.2.3    Clinical Development

11.2.4    Clinical Trials Information

11.2.5    Safety and Efficacy

11.2.6    Product Profile

11.3       NYX-2925: Aptinyx

11.3.1    Product Description

11.3.2    Other Development Activities

11.3.3    Clinical Development

11.3.4    Clinical Trials Information

11.3.5    Safety and Efficacy

11.3.6    Product Profile

11.4       Thrombomodulin alfa: Asahi Kasei Pharma America Corporation

11.4.1    Product Description

11.4.2    Other Development Activities

11.4.3    Clinical Development

11.4.4    Clinical Trials Information

11.4.5    Safety and Efficacy

11.4.6    Product Profile

11.5       LX9211: Lexicon Pharmaceuticals; Bristol Myers Squibb

11.5.1    Product Description

11.5.2    Other Development Activities

11.5.3    Clinical Development

11.5.4    Clinical Trials Information

11.5.5    Safety and Efficacy

11.5.6    Product Profile

Continued in the report...

12           Peripheral Neuropathy: 9 Major Market Analysis

12.1       Key Findings

12.2       Market Size of Peripheral Neuropathy in the 9MM

13           The United States Market Outlook

13.1       United States Market Size

13.1.1    Total Market size of Peripheral Neuropathy

13.1.2    Market Size by Therapies

13.1.3    Market Size by Type

13.1.4    Market Size by End-User

14           EU-5 Countries: Market Outlook

14.1       Germany

14.1.1    Total Market size of Peripheral Neuropathy

14.1.2    Market Size by Therapies

14.1.3    Market Size by Type

14.1.4    Market Size by End-User

14.2       France

14.2.1    Total Market size of Peripheral Neuropathy

14.2.2    Market Size by Therapies

14.2.3    Market Size by Type

14.2.4    Market Size by End-User

14.3       Italy

14.3.1    Total Market size of Peripheral Neuropathy

14.3.2    Market Size by Therapies

14.3.3    Market Size by Type

14.3.4    Market Size by End-User

14.4       Spain

14.4.1    Total Market size of Peripheral Neuropathy

14.4.2    Market Size by Therapies

14.4.3    Market Size by Type

14.4.4    Market Size by End-User

14.5       United Kingdom

14.5.1    Total Market size of Peripheral Neuropathy

14.5.2    Market Size by Therapies

14.5.3    Market Size by Type

14.5.4    Market Size by End-User

15           Australia Market Outlook

15.1       Australia Market Size

15.1.1    Total Market size of Peripheral Neuropathy

15.1.2    Market Size by Therapies

15.1.3    Market Size by Type

15.1.4    Market Size by End-User

16           China Market Outlook

16.1       China Market Size

16.1.1    Total Market size of Peripheral Neuropathy

16.1.2    Market Size by Therapies

16.1.3    Market Size by Type

16.1.4    Market Size by End-User

17           China Market Outlook

17.1       China Market Size

17.1.1    Total Market size of Peripheral Neuropathy

17.1.2    Market Size by Therapies

17.1.3    Market Size by Type

17.1.4    Market Size by End-User

18           Market Drivers

19           Market Barriers

20           SWOT Analysis of Peripheral Neuropathy

21           Appendix

22           Report Methodology

23           About Report Ocean